产品描述: | GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect |
靶点: |
PROTAC; pDC50: 8.4 (FAK);FAK |
体外研究: |
GSK215 (0.1-1000 nM; 2 h) effectively increases the FAK degradation by >90% and determines a DC50 of 1.3 nM in A549 cells. GSK215 induced degradation is proteasome and ubiquitin dependent. GSK215 (above 100 nM, 6h) reduces primarily kinases CDK7, RPS6KA3, MET and GAK[. GSK215 (100 nM, 48 h) inhibits migration, invasion and collagen deposition in A549 cells. |
体内研究: |
GSK215 (8 mg/kg; i.h.; once) degrades FAK, and shows the Cmax and tmax values of 526 ng/mL and 0.33 hours, respectively. Animal Model: Male CD1 mice (P878/881A), 7-9 weeks Dosage: 8 mg/kg Administration: Single subcutaneous injection Result: Caused a rapid and profound degradation of FAK in liver over time, with a maximal degradation of ~85% being achieved within 18 h. Endogenous FAK was found to still be reduced by ~60% at 96 h post-dose.The Cmax and tmax were 526 ng/mL and 0.33 hours, respectively. |
参考文献: |
1. Law RP, Nunes J, Chung CW, et al. Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs [published online ahead of print, 2021 Aug 20]. Angew Chem Int Ed Engl. 2021;10.1002/anie.202109237. |
溶解性: |
Soluble in DMSO |
保存条件: |
-20℃ |
备注: |
GSK215 是一种有效且具有选择性的 PROTAC 粘着斑激酶 (FAK) 降解剂,pDC50 值为 8.4。GSK215 是由 VHL E3 连接酶粘合剂和FAK 抑制剂 VS-4718 联合设计的。GSK215 诱导 FAK 快速而持久性的降解,对 FAK 水平产生长期影响,并显著降低药代动力学/药效学 (PK/PD)。 |
配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
1 mM |
1.015 ml |
5.075 ml |
10.151 ml |
5 mM |
0.203 ml |
1.015 ml |
2.03 ml |
10 mM |
0.102 ml |
0.508 ml |
1.015 ml |
50 mM |
0.02 ml |
0.102 ml |
0.203 ml |
|
注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |